Physician profile
David G Kornguth
NPI 1801820394
$46,172.69
in general payments reported to CMS, 2019-2025
25 companies · $1,935 in 2025
The $1,935 reported for 2025 was more than what 89% of Radiation Oncology providers received nationally (typical 2025 total: $172).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $8,875 · 2020: $5,919 · 2021: $1,095 · 2022: $7,073 · 2023: $20K · 2024: $874 · 2025: $1,935.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $16K · Food and Beverage: $4,013 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $2,727.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $16,470.00 |
| Food and Beverage | $4,013.27 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $2,726.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $22,617.35 | 2019-2024 | Spaceoar Vue System - 10ml, Spaceoar System |
| Palette Life Sciences, INC. | $15,816.24 | 2021-2023 | |
| Janssen Biotech, INC. | $2,495.54 | 2019-2025 | Erleada, Rybrevant, Carvykti |
| Abbvie INC. | $985.72 | 2019-2022 | |
| Dendreon Pharmaceuticals LLC | $752.46 | 2019-2023 | Provenge |
| Myovant Sciences INC. | $639.45 | 2021-2022 | |
| Sumitomo Pharma America, INC. | $497.63 | 2023-2025 | Orgovyx |
| Blue Earth Diagnostics | $408.63 | 2019-2025 | Posluma |
| Pfizer INC. | $373.48 | 2023-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $200.10 | 2019-2025 | |
| Accord Healthcare, INC. | $191.40 | 2024-2025 | |
| Telix Pharmaceuticals | $171.24 | 2025 | Illuccix |
| Teleflex LLC | $169.32 | 2024-2025 | Barrigel, Urolift |
| Ferring Pharmaceuticals INC. | $132.74 | 2025 | Adstiladrin |
| Progenics Pharmaceuticals, INC. | $127.79 | 2022-2025 | Pylarify |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Myriad Genetic Laboratories, INC. | $125.42 | 2022-2025 | Myrisk |
| Novartis Pharmaceuticals Corporation | $118.06 | 2024-2025 | |
| Janssen Scientific Affairs, LLC | $94.25 | 2023 | Balversa, Erleada |
| Astellas Pharma US INC | $86.90 | 2024-2025 | Xtandi |
| Verity Pharmaceuticals INC. | $41.63 | 2020-2025 | Trelstar |
| Profound Medical Corp. | $36.70 | 2025 | Tulsa-Pro |
| Amgen INC. | $28.91 | 2022 | |
| Inspire Medical Systems, INC. | $22.31 | 2025 | Inspire |
| Siemens Medical Solutions USA, INC. | $19.98 | 2023 | Varian Ethos Treatment Planning |
| Merck Sharp & Dohme LLC | $19.44 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Kornguth listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.